SCHEMBL4124822

SCHEMBL4124822

CN1CCN(c2cc3[nH]c(-c4nn(C5CCCCO5)cc4C(N)=O)nc3cc2F)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 2/20 0.36
FGFR1 P11362 2/20 0.35
KDR P35968 2/20 0.35
FGFR2 P21802 1/20 0.35
FGFR3 P22607 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
ATR Q13535 2/20 0.34
ABL1 P00519 1/20 0.34
OPRL1 P41146 1/20 0.34
CHEK2 O96017 2/20 0.33
PARP1 P09874 4/20 0.33
PARP2 Q9UGN5 3/20 0.33
RET P07949 1/20 0.33
ROS1 P08922 1/20 0.33
FLT3 P36888 1/20 0.33
EML4 Q9HC35 1/20 0.33
ALK Q9UM73 1/20 0.33
PRKCZ Q05513 1/20 0.33
PDGFRB P09619 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4129276 0.98 CSF1R (0.34) CSF1RFGFR1KDRFGFR2FGFR3
SCHEMBL3928879 0.92 ATR (0.40) FGFR1KDRFGFR2FGFR3ALDH1A1
SCHEMBL3926000 0.88 FGFR1 (0.37) CSF1RFGFR1KDRFGFR2FGFR3
SCHEMBL18833149 0.87 ABL1 (0.38) CSF1RFGFR1KDRFGFR2FGFR3
SCHEMBL3928184 0.86 FGFR1 (0.36) CSF1RFGFR1KDRFGFR2FGFR3
SCHEMBL3926150 0.84 MAPT (0.41) FGFR1KDRFGFR2FGFR3ALDH1A1
SCHEMBL3926395 0.84 PDE7A (0.32) FGFR1KDRFGFR2FGFR3ATR
SCHEMBL3930653 0.84 ABL1 (0.36) FGFR1KDRFGFR2FGFR3KDM4E
SCHEMBL4124975 0.83 SRPK1 (0.36) FGFR1KDRFGFR2FGFR3KDM4E
SCHEMBL4130211 0.82 SYK (0.37) FGFR1KDRFGFR2FGFR3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2041119-B1 PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF AVENTIS PHARMA SA (FR) 2017-05-10 EP disclosed
US-9126969-B2 Pyrazolylbenzimidazole derivatives, compositions containing them and use thereof AVENTIS PHARMA S.A. (FR) 2015-09-08 US disclosed
US-20090197866-A1 PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197866-A1 PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF RB1, CCNI, CDK2 CSF1R 2561/4885FGFR1 2171/4885KDR 1051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.